Invivyd, Inc.
IVVD
Positions held
Your positionsIVVD isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $206.45M | Enterprise value | $54.76M | Trailing P/E | — | Forward P/E | -1.27 |
| PEG | — | Price / book | 1.14 | Beta | 0.95 | Dividend yield | 0.00% |
| Revenue growth | 21.2% | Earnings growth | — | Gross margin | 92.2% | Operating margin | -3.2% |
| Profit margin | -1.8% | ROE | -95.9% | ROA | -45.7% | Debt / equity | 0.05 |
| Current ratio | 5.87 | Free cash flow | -$69.95M | Analyst recommendation | strong_buy | Mean target | $10.00 |
| 52w high | $3.07 | 52w low | $0.53 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $14.3M | $13.7M | $17.2M | $13.1M | $11.8M | — |
| Op margin | -320.8% | -313.9% | -73.0% | -84.0% | -127.8% | — |
| Net income | -$44.4M | -$41.4M | -$11.1M | -$10.5M | -$14.7M | — |
| Gross margin | 91.1% | 92.5% | 93.4% | 91.7% | 94.2% | — |
| Gross profit | $13.0M | $12.7M | $16.1M | $12.0M | $11.1M | — |
| Operating income | -$45.8M | -$43.1M | -$12.6M | -$11.0M | -$15.1M | — |
- Revenue +4% vs prior quarter ($14M vs $14M).
- Gross margin 91.1% (was 92.5% prior quarter).
- Operating margin compressed to -320.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $53.4M | $25.4M | $0.0M | $0.0M | — |
| Op margin | -104.0% | -696.8% | — | — | — |
| Net income | -$52.5M | -$170M | -$199M | -$241M | — |
| Gross margin | 93.0% | 93.6% | — | — | — |
| Gross profit | $49.7M | $23.8M | $0.0M | — | — |
| Operating income | -$55.6M | -$177M | -$208M | -$226M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-05 · Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
2026-09-30 · Invivyd’s Covid-directed mAb hits Phase III safety goals
2026-09-29 · Invivyd Reports Positive Phase 3 LIBERTY Results for VYD2311 and Plans Accelerated Approval Submission
2026-09-29 · Invivyd's VYD2311 Meets Primary Goals in Head-to-Head mRNA Vaccine Trial
2026-09-13 · 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
2026-09-08 · Invivyd to Participate in Upcoming September Investor Conferences
2026-09-03 · Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 · Invivyd Names Chairman Marc Elia as CEO
2026-08-13 · Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
Price (daily)
Full chart · RSI · MACD · patterns